Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06214845

Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease

Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD. Currently, there is no etiologic treatment to abort ACS. Therefore, management of ACS mostly involve a symptomatic approach including in routine, and as per recommendations, hydration, analgesics, supplemental oxygen, and transfusion.

The polymerisation of sickle haemoglobin (HbS) is one major feature in the pathogenesis of vaso-occlusion. Current guidelines recommend red blood cell exchange transfusion (REX) in patients with severe ACS in order to improve oxygenation and reduce HbS concentration to blunt sickling. REX is often preferred over simple transfusion in this setting because it rapidly reduces HbS without raising final haematocrit. There are currently two methods for REX: manual (with sequential phlebotomies and transfusions) or automated (erythrocytapheresis). The former allows a sober use of red blood cell packs, while the latter achieves haematological targets (HbS and haematocrit) quickly and more consistently, but requires a special equipment and trained staff. As a result of inflammation and intravascular hemolysis, the plasma of patients with ACS may also contain several components that promote vaso-occlusion, lung injury and organ failure, including cytokines (e.g., IL-6), free haemoglobin and free haem. Conversely, it is depleted in haptoglobin and hemopexin, which normally bind to and clear cell-free haemoglobin. The addition of therapeutic plasma exchange to erythrocytapheresis during automated REX may therefore have a dual beneficial effect in patients with overt intravascular hemolysis: i) deplete the inflammatory mediators and products of hemolysis; ii) replete haptoglobin and hemopexin. REX modalities (automated vs manual) have not been tested during ACS.

The hypothesis is that early-goal directed automated REX may accelerate the resolution of severe ACS as compared to manual REX.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Armand MEKONTSO DESSAP

Créteil, Val De Marne, 94010, France

Location contact

Armand MEKONTSO DESSAP

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Patient with major sickle cell disease syndrome (SS, SC, Sβ0 or Sβ+)
  • ACS, as defined by the association of fever and/or acute respiratory symptoms with a new pulmonary infiltrate on chest imaging
  • Requiring supplemental oxygen ≥ 2 L/min for SpO2 ≥ 95%
  • With an indication for REX given the hypoxemic ACS, as per recommendations
  • Express informed consent from the relatives or the patient himself, or emergency inclusion procedure in case of inability of patient or proxy relatives to give consent NB: Patients not affiliated to social security will be included in the study given the precarious social situation of many patients with SCD

Exclusion criteria

  • Patient having both ACS criteria and need for supplemental oxygen ≥ 2 L/min for SpO2 ≥ 95% since more than 72 hours
  • Red blood cell transfusion or REX during the current ACS episode
  • Any past medical history of delayed haemolytic transfusion reaction
  • History of < 12 transfused RBC or anti-red blood cell antibody production on the one hand and no possibility for matching on Rh/K, antibody specificity, and extended to Duffy (Fya), Kidd (Jka and Jkb) and MNS (M, N, S and s) phenotypes on the other hand (12)
  • Known legal incapacity (guardianship, curatorship)
  • Prisoners or subjects who are involuntarily incarcerated
  • Anatomical factors precluding placement of an adequate venous access
  • Known pregnancy or current lactation

Treatment and study plan

Red blood cell EXchange (REX)

Procedure

A single automated REX will be performed, as soon as possible after randomization.

Other names: Automated REX

Primary outcomes

  1. efficacy of automated (vs manual) REX to reduce time to successful weaning from both supplemental oxygen and any respiratory support (non-invasive or invasive) in adult SCD patients with hypoxemic ACS.

    Time frame: 48 hours after randomization

    Time to successful weaning from both supplemental oxygen and any respiratory support, defined as SpO2 ≥ 95% without oxygen and any respiratory support (non-invasive or invasive) during 48 hours.

Secondary outcomes

  1. Number of participants with complications during hospitalisation and within 3 months following randomisation

    Time frame: Up to 3 months

  2. Time to discharge

    Time frame: Up to 3 months

    Length of hospital stay

  3. Mortality

    Time frame: Up to 3 months

    During hospitalisation and within 28 days and 3 months following randomisation

  4. Number of participants need for noninvasive respiratory support

    Time frame: Up to 28 days

    high flow nasal oxygen, continuous positive airway pressure, or bilevel non-invasive ventilation)

  5. Number of participants readmitted for VOC or ACS

    Time frame: Up to 3 months

  6. Rate of haemoglobin S (HbS) after the first REX and at day-3

    Time frame: Up to 3 days

  7. Number of participants with change in arterial blood gases and routine biology

    Time frame: 3 and 6 days after randomization

    routine laboratory tests including: complete blood count, arterial blood gas, serum creatinine, aspartate and alanine aminotransferase (AST/ALT), total and direct bilirubin, lactate dehydrogenase (LDH), CRP; blood electrolyte panel

  8. Number of participants with improved chest imaging

    Time frame: 3 and 6 days after randomisation

Study contacts

Contact information is provided by the study sponsor or research team.

Armand MEKONTSO DESSAP

CONTACT

[email protected]

+33 1 45 17 85 11

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease: a Multicentre, Randomised, Clinical Trial

Acronym: ARCAD

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 22, 2024
Registry last updated
Jan 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.